Event
Pharmacology and acute effects of different psychedelics
Current clinical trials with psychedelics mostly use psilocybin. However, there are other classic psychedelics such as LSD, DMT and mescaline that may be useful. The presentation will give an overview on the substances currently used in clinical trials and then focus on the acute effect characteristics of different psychedelics.
Speakers
Professor of Clinical Pharmacology and Internal Medicine
Prof. Dr. Matthias Liechti
University Hospital, Basel
View Speaker Profile
Related Events
In conversation with a recipient of Psychedelic therapy integrated with a contextual behavioural therapy approach for complex trauma
Key Notes
Diana sought support in preparing and integrating her own psychedelic healing. She now volunteers to speak out about the benefits of psilocybin tru…
‘Storming the gates of heaven’ – the challenges of psychedelic therapy from a psychotherapeutic perspective
Key Notes
The benefits of psychedelic therapy have been very well documented over the past number of years, with cutting edge scientific research showing the…
Somatics & Psychedelics: How to use body awareness to heal trauma and integrate and unfold intense experiences
Key Notes
This presentation will introduce the great potential that many of the somatic practices carry and how they could be implemented in conjunction with…
Mechanisms of Action of Psychedelics – Implication for Psychedelic-Assisted Therapy
Key Notes
Research on the clinical application of psychedelics is gaining momentum. However major knowledge gaps remain regarding the mechanisms of action un…
The causal relevance of psychedelic experiences to therapeutic benefits
Key Notes
Increasing evidence suggests that psychedelic-assisted psychotherapy can durably reduce symptoms of anxiety, depression, and addiction. Despite inc…
The German EPIsoDE-Trial – Study design, rationale and current status
Key Notes
This presentation will go over the preliminary evidence for the efficacy and safety of psilocybin, a serotonergic psychedelic acting as a partial 5…
Psychological and neuroscience based approaches to the treatment of depression with psychedelics
Key Notes
Recent integrative psychological and neuroscientific approaches to depression highlight that the self is a core dimension of depression. The self i…
What octopuses and psychedelics teach us about the social brain
Key Notes
Although an octopus brain has neither a nucleus accumbens, nor a dorsal raphe, nor a cerebral cortex, recently we have shown that the acute prosoci…
A double-edged sword? Potential risks associated with key benefits of psychedelic treatments
Key Notes
View event
The State and Future of Psychedelic Therapist Training
Key Notes
While research clearly acknowledges the therapist’s indispensable role of before, during, and after psychedelic therapy sessions, the unique proc…
Whatever Next and Closer to my Self – The Transparent Senses and the ‘Second Skin’: Implications for the Case of Depersonalisation
Key Notes
In his seminal paper ‘Whatever next? Predictive brains, situated agents, and the future of cognitive science’ Andy Clark (2013) argued that the…
Ecological consciousness, phenomenology and translational neurosciences: What role for psychedelics for the shaping of a view on consciousness beyond the individual and across species?
Key Notes
“If my consciousness has a body why wouldn’t other bodies have consciousness?” this quote of the French phenomenologist Maurice Merleau-Ponty…
Rigorously evaluating claims about the scope and history of traditional psychedelic use
Key Notes
A common assumption among scientists and popularizers is that indigenous peoples around the world have used psychedelics for millennia, often for s…
